التفاصيل البيبلوغرافية
| العنوان: |
A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI‐1 trial. |
| المؤلفون: |
Copland, Mhairi, Ariti, Cono, Thomas, Ian F., Upton, Laura, Sydenham, Mia, Mehta, Priyanka, Islam, Shahid, Kjeldsen, Lars, Burnett, Alan K., Hills, Robert K., Russell, Nigel, Dennis, Mike |
| المصدر: |
British Journal of Haematology; Mar2024, Vol. 204 Issue 3, p871-876, 6p |
| مصطلحات موضوعية: |
ACUTE myeloid leukemia, OLDER patients, AZACITIDINE, LENALIDOMIDE, CYTARABINE |
| مستخلص: |
Summary: Improving outcomes for older patients with acute myeloid leukaemia remains an unmet need. As part of the LI‐1 trial, we evaluated lenalidomide (LEN) in combination with low‐dose cytosine arabinoside (LDAC) in patients aged >60 years unfit for intensive therapy and compared this to LDAC alone. Two hundred and two patients, randomised 1:1, were evaluable. Overall response rate (CR + CRi) was higher for LDAC + LEN versus LDAC (26% and 13.7% respectively p = 0.031). However, there was no difference in overall survival between the arms (14% and 11.5% at 2 years for LDAC + LEN and LDAC respectively). The addition of LEN was associated with increased toxicity and supportive care requirements. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder